1. Home
  2. SNY vs SYK Comparison

SNY vs SYK Comparison

Compare SNY & SYK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sanofi ADS

SNY

Sanofi ADS

HOLD

Current Price

$49.34

Market Cap

119.4B

Sector

Health Care

ML Signal

HOLD

Logo Stryker Corporation

SYK

Stryker Corporation

HOLD

Current Price

$363.90

Market Cap

141.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNY
SYK
Founded
1994
1941
Country
France
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.4B
141.2B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SNY
SYK
Price
$49.34
$363.90
Analyst Decision
Buy
Buy
Analyst Count
4
15
Target Price
$61.50
$434.64
AVG Volume (30 Days)
2.3M
1.7M
Earning Date
10-24-2025
01-27-2026
Dividend Yield
3.23%
0.92%
EPS Growth
105.93
N/A
EPS
8.67
7.61
Revenue
$53,890,648,839.00
$24,381,000,000.00
Revenue This Year
$2.37
$12.01
Revenue Next Year
$6.51
$8.59
P/E Ratio
$11.25
$47.83
Revenue Growth
N/A
10.95
52 Week Low
$44.62
$329.16
52 Week High
$60.12
$406.19

Technical Indicators

Market Signals
Indicator
SNY
SYK
Relative Strength Index (RSI) 46.53 45.54
Support Level $48.89 $364.49
Resistance Level $50.43 $374.10
Average True Range (ATR) 0.73 6.22
MACD -0.15 0.03
Stochastic Oscillator 19.29 30.67

Price Performance

Historical Comparison
SNY
SYK

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

About SYK Stryker Corporation

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.

Share on Social Networks: